Amphastar Pharmaceuticals, Inc. (AMPH) SEC Filing 8-K Material Event for the period ending Tuesday, April 19, 2022

Amphastar Pharmaceuticals, Inc.

CIK: 1297184 Ticker: AMPH

View differences made from one to another to evaluate Amphastar Pharmaceuticals, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Amphastar Pharmaceuticals, Inc..


Assess how Amphastar Pharmaceuticals, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Amphastar Pharmaceuticals, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 8-K Corporate News

Ticker: AMPH
CIK: 1297184
Form Type: 8-K Corporate News
Accession Number: 0001297184-22-000021
Submitted to the SEC: Fri Apr 22 2022 4:13:51 PM EST
Accepted by the SEC: Fri Apr 22 2022
Period: Tuesday, April 19, 2022
Industry: Pharmaceutical Preparations
  1. New Agreement

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: